NEUROINFLAMMATION MECHANISMS, CLINICAL IMPLICATIONS, AND THERAPEUTIC APPROACHES

neuroinflamationkapak

NEUROINFLAMMATION IN EPILEPSY: WHAT DO WE KNOW?

Bengi Gül Türk1
Özdem Ertürk Çetin2

1İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Neurology, İstanbul, Türkiye
2 University of Health Sciences, Hamidiye Faculty of Medicine, Sancaktepe Şehit Prof Dr. İlhan Varank Training and Research Hospital, Department of Neurology, İstanbul, Türkiye

Türk BG, Ertürk Çetin Ö. Neuroinflammation in Epilepsy: What Do We Know?. In: Şahin Ş editor. Neuroinflammation. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.49-63.

ABSTRACT

Epilepsi, dünya genelinde her yaş grubundan yaklaşık 50 milyon kişiyi etkilediği düşünülen kronik bir beyin hastalığıdır. Klinik ve prognostik açıdan oldukça heterojen bir yapıya sahip olan bu hastalığın etiyolojik nedenleri de çeşitlilik göstermektedir. Son yıllarda artan klinik ve deneysel kanıtlar, beyindeki inflamatuar süreçlerin nöbetlerin ve epilepsinin patofizyolojisinde ortak ve önemli bir mekanizma oluşturabileceği hipotezini desteklemiştir.

Deneysel ve klinik çalışmalar, inflamasyon ve epilepsi arasındaki ilişkinin bimodal bir etkileşim sergilediğini ortaya koymuştur. Bu etkileşimin bir tarafında, inflamasyonun epilepsi ve/veya epileptogenez sürecine yol açması fikri yer alırken diğer uçta ise, tekrarlayan nöbetlerin MSS içinde inflamatuar süreçleri tetiklemesi yer almaktadır. Yani inflamasyonun epilepsinin nedeni olabileceği kadar bir sonucu da olabileceğini destekleyen hipotezler ve çalışmalar bildirilmiştir.

Epilepsi patofizyolojisi, yalnızca merkezi sinir sistemiyle sınırlı kalmayıp, sistemik dokularda da aktif olan inflamatuvar moleküller ve yollarla etkileşim halindedir. Bu süreçte, sitokinler, kemokinler ve diğer inflamatuvar moleküllerin önemli roller üstlendiği gösterilmiştir. Ancak, bu alanda hâlâ yanıt bekleyen birçok kritik soru bulunmaktadır.

Keywords: Epilepsy; Seizure; Inflammation

Referanslar

  1. World Health Organization. “Epilepsy.”
  2. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French, J, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017;58(4):512-521. [Crossref]  [PubMed]  [PMC]
  3. Fisher RS. The New Classification of Seizures by the International League Against Epilepsy 2017. Curr Neurol Neurosci Rep. 2017;17(6):48. [Crossref]  [PubMed]
  4. Wirrell E, Tinuper P, Perucca E, Moshé SL. Introduction to the epilepsy syndrome papers. Epilepsia, 2022;63(6):13301332. [Crossref]  [PubMed]
  5. Rana A, Musto AE. The role of inflammation in the development of epilepsy. Journal of Neuroinflammation, 2018;15(1):144. [Crossref]  [PubMed]  [PMC]
  6. Choi J, Koh S. Role of brain inflammation in epileptogenesis. Yonsei Medical Journal, 2008;49(1):1-18. [Crossref]  [PubMed]  [PMC]
  7. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nature Reviews Neurology, 2011;7(1):31-40. [Crossref]  [PubMed]  [PMC]
  8. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-472. [Crossref]  [PubMed]
  9. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. [Crossref]  [PubMed]
  10. Beghi E, Carpio A, Forsgren L, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010;51(4):671-675. [Crossref]  [PubMed]
  11. Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. Journal of Neuroscience. 2023;23:955-960. [Crossref]  [PubMed]  [PMC]
  12. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration.” Nature Reviews Neuroscience. 2001;2:734-744.
  13. Nguyen MD, Julien JP, Rivest S. “Innate immunity: the missing link in neuroprotection and neurodegeneration?” Nature Reviews Neuroscience. 2002;3:216-227. [Crossref]  [PubMed]
  14. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Progress in Neurobiology. 2001;63:125-149. [Crossref]  [PubMed]
  15. Peltola J, Eriksson K, Keränen T. Cytokines and seizures. Arch Neurol. 2001;58(7):1168-1169. [Crossref]  [PubMed]
  16. Minami M, Kuraishi Y, Satoh M. Effects of kainic acid on messenger RNA levels of IL-1beta, IL-6, TNF alpha and LIF in the rat brain. Biochemical and Biophysical Research Communications. 1991;176:593-598. [Crossref]  [PubMed]
  17. Gahring LC, White SH, Skradski SL, Carlson NG, Rogers SW. Interleukin-1beta in the brain is induced by audiogenic seizure. Neurobiol Dis. 1997;3:263-269. [Crossref]  [PubMed]
  18. Plata-Salaman CR, Ffrench-Mullen JM. Interleukin-1be ta depresses calcium currents in CA1 hippocampal neurons at pathophysiological concentrations. Brain Res Bull. 1992;29:221-223. [Crossref]  [PubMed]
  19. Crespel A, Coubes P, Rousset MC, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res. 2002;952:159-169. [Crossref]  [PubMed]
  20. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis. 2007;26(3):497–511. [Crossref]  [PubMed]
  21. Ravizza T, Gagliardi B, Noé F, et al. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis. 2008;29(1):142–160. [Crossref]  [PubMed]
  22. van Gassen KL, de Wit M, Koelman JH, et al. Possible role of the innate immunity in temporal lobe epilepsy. Epilepsia. 2008;49(6):1055–1065. [Crossref]  [PubMed]
  23. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005;46(11):1724– 1743. [Crossref]  [PubMed]
  24. Dubé C, Vezzani A, Behrens M, Bartfai T, Baram TZ. Interleukin-1beta contributes to the generation of experimental febrile seizures. Ann Neurol. 2005;57(1):152–155. [Crossref]  [PubMed]  [PMC]
  25. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis. 2007;26(3):497–511. [Crossref]  [PubMed]
  26. Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1443–1474. [Crossref]  [PubMed]
  27. Orsini A, Foiadelli T, Carli N, et al. Rasmussen’s encephalitis: From immune pathogenesis towards targeted-therapy. Seizure. 2020;81:76–83. [Crossref]  [PubMed]
  28. Varadkar S, Bien CG, Kruse CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 2014;13(2):195–205. [Crossref]  [PubMed]  [PMC]
  29. Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128(Pt 3):454–471. [Crossref]  [PubMed]
  30. Tang C, Yang W, Luan G. Progress in pathogenesis and therapy of Rasmussen’s encephalitis. Acta Neurol Scand. 2022;146(6):761–766. [Crossref]  [PubMed]
  31. Steriade C, Britton J, Dale RC, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia. 2020;61(7):1341–1351. [Crossref]  [PubMed]
  32. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. [Crossref]  [PubMed]  [PMC]
  33. Husari KS, Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019;16(3):685–702. [Crossref]  [PubMed]  [PMC]
  34. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54(6):1028–1035. [Crossref]  [PubMed]
  35. Yao L, Yue W, Xunyi W, et al. Clinical features and longterm outcomes of seizures associated with autoimmune encephalitis: a follow-up study in East China. J Clin Neurosci. 2019;68:73–79. [Crossref]  [PubMed]
  36. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900. [Crossref]  [PubMed]
  37. Singhi P. Infectious causes of seizures and epilepsy in the developing world. Developmental Medicine & Child Neurology. 2011;53(7):600-9. [Crossref]  [PubMed]
  38. Vezzani A, Fujinami RS, White HS, et al. Infections, inflammation and epilepsy. Acta Neuropathol. 2016;131(2):211-234. [Crossref]  [PubMed]  [PMC]
  39. Linnoila J, Pulli B, Armangué T, et al. Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. Neurol Neuroimmunol Neuroinflamm. 2018;6(2):e529. [Crossref]  [PubMed]  [PMC]
  40. Maldonado M, Baybis M, Newman D, et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiology of Disease. 2003;14:279-290. [Crossref]  [PubMed]
  41. Crespel A, Coubes P, Rousset MC, et al. “Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis.” Brain Research, 2002;952:159-169. [Crossref]  [PubMed]
  42. Sun L, Shan W, Yang H, Liu R, Wu J, Wang Q. The role of neuroinflammation in post-traumatic epilepsy. Frontiers in Neurology. 2021;12:646152. [Crossref]  [PubMed]  [PMC]
  43. Mosini AC, Sanabria V, Nakamura TKE, et al. Posttraumatic epilepsy: Integrating clinical, inflammatory, and genetic profiles in traumatic brain injury patients. Epilepsy Res. 2024;205:107402. [Crossref]  [PubMed]
  44. Javalgekar M, Jupp B, Vivash L, O’Brien TJ, Wright DK, Jones NC, Ali I. Inflammasomes at the crossroads of traumatic brain injury and post-traumatic epilepsy. Journal of Neuroinflammation. 2024;21(1):172. [Crossref]  [PubMed]  [PMC]
  45. Dulla CG, Pitkänen A. Novel approaches to prevent epileptogenesis after traumatic brain injury. Neurotherapeutics, 2021;18(3):1582-1601. [Crossref]  [PubMed]  [PMC]
  46. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523. [Crossref]  [PubMed]
  47. Turrin NP, Rivest S. Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy. Neurobiol Dis. 2004;16(2):321-334. [Crossref]  [PubMed]
  48. Tan TH, Perucca P, O’Brien TJ, Kwan P, Monif M. Inflammation, ictogenesis, and epileptogenesis: An exploration through human disease. Epilepsia. 2021;62(2):303-324. [Crossref]  [PubMed]
  49. Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(3):1604-1613. [Crossref]  [PubMed]
  50. Brunson KL, Avishai-Eliner S, Baram TZ. ACTH treatment of infantile spasms: mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol. 2002;49:185–197. [Crossref]  [PubMed]  [PMC]
  51. Mikati MA, Kurdi R, El-Khoury Z, Rahi A, Raad W. Intravenous immunoglobulin therapy in intractable childhood epilepsy: open-label study and review of the literature. Epilepsy Behav. 2010 Jan;17(1):90–94. [Crossref]  [PubMed]